Literature DB >> 17352248

Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma.

Elisabetta Cenni1, Francesca Perut, Donatella Granchi, Sofia Avnet, Ilaria Amato, Maria Luisa Brandi, Armando Giunti, Nicola Baldini.   

Abstract

BACKGROUND: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma.
MATERIALS AND METHODS: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated.
RESULTS: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2.
CONCLUSION: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352248

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Int J Cardiol       Date:  2010-08-02       Impact factor: 4.164

2.  Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.

Authors:  C G Stoehr; R Stoehr; A Hartmann; F Hofstaedter; K Junker; H Blaszyk; W F Wieland; W Otto; S Denzinger; B Walter
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-28       Impact factor: 4.553

3.  Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma.

Authors:  Maria Volkova; Ilya Tsimafeyeu; Anna Olshanskaya; Yulia Khochenkova; Eliso Solomko; Saida Ashuba; Vsevolod Matveev; Dmitry Khochenkov
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

4.  Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

Authors:  Tram Anh Tran; Hon Sing Leong; Andrea Pavia-Jimenez; Slavic Fedyshyn; Juan Yang; Blanka Kucejova; Sharanya Sivanand; Patrick Spence; Xian-Jin Xie; Samuel Peña-Llopis; Nicholas Power; James Brugarolas
Journal:  Mol Cell Biol       Date:  2016-06-15       Impact factor: 4.272

5.  Regulation of blood vessel versus lymphatic vessel growth in the cornea.

Authors:  Eui-Sang Chung; Daniel R Saban; Sunil K Chauhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-21       Impact factor: 4.799

6.  HIF-1α effects on angiogenic potential in human small cell lung carcinoma.

Authors:  Jun Wan; Huiping Chai; Zaicheng Yu; Wei Ge; Ningning Kang; Wanli Xia; Yun Che
Journal:  J Exp Clin Cancer Res       Date:  2011-08-15

7.  A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.

Authors:  D Li; X Wei; K Xie; K Chen; J Li; J Fang
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

8.  Interleukin-1β induces fibroblast growth factor 2 expression and subsequently promotes endothelial progenitor cell angiogenesis in chondrocytes.

Authors:  Szu-Yu Chien; Chun-Yin Huang; Chun-Hao Tsai; Shih-Wei Wang; Yu-Min Lin; Chih-Hsin Tang
Journal:  Clin Sci (Lond)       Date:  2016-01-25       Impact factor: 6.124

9.  Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions.

Authors:  Kelly Aukes; Cynthia Forsman; Nicholas J Brady; Kristina Astleford; Nicholas Blixt; Deepali Sachdev; Eric D Jensen; Kim C Mansky; Kathryn L Schwertfeger
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

Review 10.  Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.

Authors:  Bao T Le; Prithi Raguraman; Tamer R Kosbar; Susan Fletcher; Steve D Wilton; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.